Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Date

14 Sep 2024

Session

Poster session 02

Topics

Clinical Research;  Immunotherapy

Tumour Site

Head and Neck Cancers

Presenters

Jared Weiss

Citation

Annals of Oncology (2024) 35 (suppl_2): S613-S655. 10.1016/annonc/annonc1594

Authors

J. Weiss1, J. Kaczmar2, K.J. Harrington3, R. Mehra4, F. Worden5, R. Zinner6, A. Giri7, H. Kang8, S. Najeeb9, T. Panella10, A. Sukari11, C. Grant12, V. Kaur13, S. Jones14, D. Schaaf15, K. Price16

Author affiliations

  • 1 Medical Oncology Department, UNC - Lineberger Cancer Center, NC 27514 - Chapel Hill/US
  • 2 Department Of Medicine, MUSC Health Hollings Cancer Center, North Charleston/US
  • 3 Dept. Of Radiotherapy And Imaging, ICR - Institute of Cancer Research - Chester Beatty Laboratories, SW3 6JB - London/GB
  • 4 Medicine Department, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, 21201 - Baltimore/US
  • 5 Medical Oncology, The University of Michigan Health Rogel Cancer Center, 48109 - Ann Arbor/US
  • 6 Medical Oncology, University of Kentucky, 40536 - Lexington/US
  • 7 Department Of Hematology/oncology, Fox Chase Cancer Center - Main Campus, 19111-2497 - Philadelphia/US
  • 8 Medicine Department, University of California San Francisco, CA, 94143 - San Francisco/US
  • 9 Department Of Hematology/oncology, WVU Cancer Institute, 26506 - Morgantown/US
  • 10 Department Of Hematology/oncology, UT - The University of Tennessee Medical Center, 37920 - Knoxville/US
  • 11 Hematology-oncology, Karmanos Cancer Institute, 48201 - Detroit/US
  • 12 Medical Oncology, St James's Hospital, 8 - Dublin/IE
  • 13 Hematology-oncology Dept., UVA - University of Virginia - School of Medicine - Division of Hematology & Oncology, 22908-0716 - Charlottesville/US
  • 14 Clinical Operations, PDS Biotechnology, 07932 - Florham Park/US
  • 15 Medical Affairs, PDS Biotechnology, 08540 - Florham Park/US
  • 16 Medical Oncology, Mayo Clinic, 55905 - Rochester/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 879P

Background

Immune checkpoint inhibitor (ICI) pembrolizumab with or without chemotherapy is first-line (1L) treatment for most patients with unresectable, recurrent or metastatic (R/M) HNSCC. PDS0101 (Versamune® HPV) is a novel, investigational HPV16-targeted therapeutic cancer vaccine that stimulates a potent, targeted T cell attack against HPV16-positive cancers.

Methods

We conducted a single-arm phase II study evaluating PDS0101 and pembrolizumab for 1L HPV16-positive R/M HNSCC. Subjects received pembrolizumab 200 mg IV Q3W with PDS0101 1 mL SC administered concurrently during Cycles 1, 2, 3, 4, and 12 and pembrolizumab monotherapy for all other Cycles up to Cycle 35 (approx. 2 years). The primary study endpoint was confirmed BOR per RECIST 1.1. Herein we report OS and update data on safety, ORR, and PFS in ICI naïve subjects.

Results

The study has completed enrollment. Ten subjects remain on treatment and 21 subjects are in long-term survival follow up. Demographics are previously reported; of note, 60.4% CPS 1-19 and 39.6% CPS ≥20. The median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%. Eighteen subjects (34%) had confirmed response by investigator assessment (4 CR and 14 PR). In the CPS≥20 cohort, 10/21 (48%) subjects had a confirmed response. The median PFS was 6.3 months (95% CI 3.1, 14.1). In the CPS≥20 cohort, median PFS was 14.1 months. Updated safety will be presented; no new safety signals emerged and the most common TRAEs remain injection site reactions, fatigue, headache, and pruritis with only 13% of subjects experiencing Grade ≥3 TRAEs. No subject had Grade 5 TRAE.

Conclusions

Enrollment is complete. Pembrolizumab plus PDS0101 shows excellent tolerability. Survival data are favorable compared to historic expectations, especially when PD-L1 levels of accrued subjects are considered. These results support further evaluation in a randomized phase III study.

Clinical trial identification

NCT04260126.

Editorial acknowledgement

Legal entity responsible for the study

PDS Biotechnology Corporation.

Funding

PDS Biotechnology Corporation.

Disclosure

J. Weiss: Financial Interests, Personal, Speaker, Consultant, Advisor: PDS Biotechnology. J. Kaczmar: Financial Interests, Personal, Advisory Board: PDS Biosciences, EMD serono; Financial Interests, Institutional, Local PI: EMD, PDS, Bicara, Merck, Replimmune; Financial Interests, Personal, Coordinating PI, research funding for IIT at MUSC: Signatera. K.J. Harrington: Financial Interests, Institutional, Steering Committee Member: GSK, AZ, MSD, Merck-Serono; Financial Interests, Institutional, Advisory Board: AZ, MSD, Merck Serono; Financial Interests, Institutional, Funding: AZ; Financial Interests, Institutional, Local PI: AZ, MSD; Financial Interests, Institutional, Invited Speaker: MSD, Merck-Serono; Financial Interests, Institutional, Research Funding: Merck-Serono; Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck-Serono. R. Mehra: Financial Interests, Personal, Speaker, Consultant, Advisor: Coherus Biosciences, Janssen Oncology, Merck KGaA; Financial Interests, Institutional, Research Funding: AZ, Merck; Non-Financial Interests, Personal, Advisory Role: AZ. F. Worden: Financial Interests, Personal, Advisory Board: PDS Biotechnology. H. Kang: Financial Interests, Personal, Other, Consultant: PIN therapeutics, Hanmi Pharmaceuticals; Financial Interests, Personal, Other, Data safety monitoring board: MitoImmune; Financial Interests, Personal, Advisory Board: HLB group, LG Chem, Coherus; Financial Interests, Institutional, Coordinating PI: Elevar therapeutics; Financial Interests, Institutional, Local PI: Eli Lilly, PDS biotechnology, Ayala, Remix Therapeutics, Merus; Financial Interests, Institutional, Trial Chair: NeoImmune Tech; Non-Financial Interests, Member: American Society of Clinical Oncology, American Association for Cancer Research, International Thyroid Oncology Group, American Thyroid Association, Society of Immunotherapy of Cancer. C. Grant: Financial Interests, Personal, Advisory Board: Roche Pharmaceuticals, BMS; Financial Interests, Personal, Advisory Role: Roche Pharmaceuticals. S. Jones, D. Schaaf: Financial Interests, Personal, Stocks/Shares: PDS Biotechnology. K. Price: Non-Financial Interests, Institutional, Advisory Role: InSitu Biologics; Financial Interests, Institutional, Speaker, Consultant, Advisor: PDS Biotechnology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.